Erica DiNapoli

Articles

Parsaclisib Yields Encouraging Clinical Activity in Marginal Zone Lymphoma

January 21st 2021

Tycel Phillips, MD, highlighted the key findings of the phase 2 CITADEL-204 trial.

1-Year DFS Rates Similar Between Ibrutinib and Placebo Following Ibrutinib/Venetoclax in CLL

January 21st 2021

William G. Wierda, MD, PhD, discusses the latest CAPTIVATE findings in patients with chronic lymphocytic leukemia.

Emerging Strategies Seek to Build on the Benefit Achieved With Radiation in Lung Cancer

January 19th 2021

Katie Keane, MD, highlights the evolving role of stereotactic body radiation therapy in the treatment of patients with stage I lung cancer, the utilization of immunotherapy with chemoradiation in stage III disease, and research evaluating radiation in those with oligometastatic disease.

Stadtmauer Spotlights the Explosion of BCMA-Directed Therapies in Multiple Myeloma

January 14th 2021

Edward A. Stadtmauer, MD, highlights the emergence of several BCMA-directed therapies, such as monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies, and how outcomes for patients with multiple myeloma have improved significantly.

Aggressive Treatment Approaches May Move Dial in Metastatic Colon Cancer

January 13th 2021

Michael J. Cavnar, MD, highlights the role of surgery in colon cancer, the role of tumor sidedness in informing surgical decisions, and research efforts that are being done to evaluate the utility of hepatic artery infusion pumps.

Addition of Darolutamide May Augment Standard Treatment for Localized, Very High-Risk Prostate Cancer

January 11th 2021

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the benefit achieved with standard-of-care radiation therapy plus androgen deprivation therapy with a luteinising hormone-releasing hormone analogue.

Need for Molecular Testing in Lung Cancer Is Underscored as Additional Targets Emerge

January 8th 2021

Yujie Zhao, MD, PhD, highlights molecular testing and how it's a critical component of the treatment selection process in lung cancer, as a host of effective drugs have since been developed to target alterations such as ALK, ROS1, and RET.

Mobile Intervention for Adherence to Aromatase Inhibitors Misses Mark in Breast Cancer

January 4th 2021

Julie Gralow, MD, discusses exciting research in HER2-positive breast cancer.

Hunt for Predictive Biomarkers for T-DM1 in HER2+ Breast Cancer Continues

January 4th 2021

Ian E. Krop, MD, PhD, highlights the impact of the pivotal KATHERINE trial on the adjuvant treatment of patients with early-stage HER2-positive breast cancer and other recent advances that are moving the needle forward.

Role for Somatic, Inherited Genetic Testing in Prostate Cancer Continues to Grow

January 3rd 2021

Leonard G. Gomella, MD, discusses the growing importance of genetic testing in prostate cancer.

x